title: Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice.
abstract: Quantitative characterization of atherosclerotic plaque composition with standard histopathological methods remains limited to sectioned plaques. Raman spectroscopy enables nondestructive quantification of atherosclerotic plaque composition. We used Raman spectroscopy to study the effects of diet and lipid-lowering therapy on plaque development in apolipoprotein (APO) E*3-Leiden transgenic mice. Raman spectra were obtained over the full width and entire length of the ascending aorta and aortic arch. Spectra were modeled to calculate the relative dry weights of cholesterol and calcium salts, and quantitative maps of their distribution were created. In male mice (n=20) that received a high-fat/high-cholesterol (HFC) diet for 0, 2, 4, or 6 months, Raman spectroscopy showed good correlation between cholesterol accumulation and total serum cholesterol exposure (r approximately 0.87, P<0.001). In female mice (n=10) that were assigned to an HFC diet, with or without 0.01% atorvastatin, a strong reduction in cholesterol accumulation (57%) and calcium salts (97%) (P<0.01) was demonstrated in the atorvastatin-treated group. In conclusion, Raman spectroscopy can be used to quantitatively study the size and distribution of depositions of cholesterol and calcification in APOE*3-Leiden transgenic mice. This study encourages Raman spectroscopy for the quantitative investigation of atherosclerosis and lipid-lowering therapy in larger animals or humans in vivo.
authors.affiliation: Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: S W
authors.initials: SW
authors.lastname: van De Poll
authors.forename: T J
authors.initials: TJ
authors.lastname: Römer
authors.forename: O L
authors.initials: OL
authors.lastname: Volger
authors.forename: D J
authors.initials: DJ
authors.lastname: Delsing
authors.forename: T C
authors.initials: TC
authors.lastname: Bakker Schut
authors.forename: H M
authors.initials: HM
authors.lastname: Princen
authors.forename: L M
authors.initials: LM
authors.lastname: Havekes
authors.forename: J W
authors.initials: JW
authors.lastname: Jukema
authors.forename: A
authors.initials: A
authors.lastname: van Der Laarse
authors.forename: G J
authors.initials: GJ
authors.lastname: Puppels
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001011:Aorta / Q000473:pathology; D053318:Apolipoprotein E3; D001057:Apolipoproteins E / Q000235:genetics; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000473:pathology*; D000069059:Atorvastatin; D002114:Calcinosis / Q000473:pathology; D002784:Cholesterol / Q000032:analysis; D004036:Diet, Atherogenic; D018450:Disease Progression; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D011758:Pyrroles / Q000627:therapeutic use; D015203:Reproducibility of Results; D013059:Spectrum Analysis, Raman / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D053318:Apolipoprotein E3; D001057:Apolipoproteins E; D006538:Heptanoic Acids; D011758:Pyrroles; C052720:apolipoprotein E3 (Leidein); D002784:Cholesterol; D000069059:Atorvastatin